AMG National Trust Bank Has $2.60 Million Stake in Sanofi SA (SNY)
AMG National Trust Bank raised its stake in Sanofi SA (NYSE:SNY) by 11.1% in the fourth quarter, Holdings Channel reports. The fund owned 60,360 shares of the company’s stock after purchasing an additional 6,043 shares during the quarter. AMG National Trust Bank’s holdings in Sanofi were worth $2,595,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SNY. BlackRock Inc. raised its holdings in shares of Sanofi by 47.6% in the second quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock worth $107,100,000 after acquiring an additional 720,523 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of Sanofi in the second quarter worth $22,558,000. State Street Corp raised its holdings in shares of Sanofi by 401.3% in the second quarter. State Street Corp now owns 41,183 shares of the company’s stock worth $1,972,000 after acquiring an additional 32,967 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Sanofi in the second quarter worth $2,702,000. Finally, Toronto Dominion Bank raised its holdings in shares of Sanofi by 4.6% in the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after acquiring an additional 180 shares during the last quarter. 9.07% of the stock is owned by institutional investors.
A number of research firms have recently weighed in on SNY. TheStreet cut Sanofi from a “b-” rating to a “c+” rating in a report on Tuesday. Zacks Investment Research cut Sanofi from a “hold” rating to a “sell” rating in a report on Wednesday. Sanford C. Bernstein reiterated a “market perform” rating and issued a $45.00 target price (down from $50.00) on shares of Sanofi in a research note on Thursday, February 8th. ValuEngine lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 6th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company. Sanofi has an average rating of “Hold” and a consensus target price of $49.33.
Sanofi (NYSE:SNY) last released its earnings results on Wednesday, February 7th. The company reported $0.62 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.07). The business had revenue of $8.69 billion during the quarter, compared to analyst estimates of $8.65 billion. Sanofi had a net margin of 23.25% and a return on equity of 37.09%. The business’s revenue for the quarter was down 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.25 earnings per share. equities analysts predict that Sanofi SA will post 3.37 EPS for the current fiscal year.
The firm also recently announced an annual dividend, which will be paid on Monday, June 4th. Investors of record on Thursday, May 10th will be paid a $1.8609 dividend. This is a positive change from Sanofi’s previous annual dividend of $1.58. This represents a yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. Sanofi’s dividend payout ratio is presently 30.14%.
COPYRIGHT VIOLATION WARNING: This story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://theolympiareport.com/2018/02/15/amg-national-trust-bank-has-2-60-million-stake-in-sanofi-sa-sny.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.